Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences
APX005M Demonstrates Potent CD40-Induced Immune Activation and Anti-Tumor Activity
San Carlos, Calif., April 13, 2016 — Apexigen, Inc., — a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer, announced today that data for the Company’s lead immuno-oncology program, APX005M, will be presented at two upcoming cancer conferences. APX005M targets CD40, a key immune co-stimulatory receptor essential to regulating the activation of both innate and adaptive immune responses against cancer.
- On April 14: Xiaodong Yang, M.D., Ph.D., President and CEO, will deliver an invited podium presentation at the Immune Checkpoint Modulation & Combination Therapies Conference taking place April 12-14 in London, England.
- On April 20: Apexigen scientists will present two posters at the AACR Annual
Meeting 2016 taking place April 16-20 in New Orleans, LA.
- Section 22, Poster 4867: “The CD40 agonistic antibody APX005M ‘licenses’ antigen presenting cells to promote tumor-specific T-cell responses”
- Section 26, Poster 5004: “APX005M, a humanized anti-CD40 antibody with strong immune-modulatory activities capable of tumor eradication in vivo”
“Anti-CD40 antibodies have been shown to be potent boosters of anti-tumor immune response and capable of inhibiting multiple tumor types as a single agent and in combination with immunotherapeutic agents in tumor models,” said Dr. Yang. “We believe the ability of APX005M to control and regulate both the innate and adaptive immune systems may position it as a key component of immuno-oncology therapy. We are currently conducting a Phase 1 dose-escalation study of APX005M in patients with advanced solid tumors and look forward to reporting on our clinical progress.”
APX005M is a novel, humanized monoclonal antibody designed to reverse the systemic immune suppression that typically affects cancer patients. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 initiates and amplifies a complex, multi-cellular immune response bringing components of both immune systems to work in concert against cancer, activating antigen-presenting cells (i.e., dendritic cells, monocytes and B-cells) and resulting in cancer-specific T-cell responses. APX005M is currently in Phase 1 clinical development for the treatment of solid tumors.
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that could harness the patient’s immune system to combat and eradicate cancer. APX005M and the Company’s additional preclinical programs were discovered using APXiMAB™, Apexigen’s proprietary product discovery platform. This platform has enabled the Company and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Six product candidates discovered using APXiMAB™ are currently in clinical development, either internally by Apexigen or by its partners. For more information, please visit www.apexigen.com.
Vice President, Business Development
+1 650-931-6236, ext. 502
For Media Inquiries
Karen L. Bergman